Skip to content

Mesalamine

5-ASA Anti-Inflammatory — Gastrointestinal

Data last refreshed: (DrugCentral release 2024-11-01) · Article last edited:

Key facts

Mesalamine is an ofp drug in the Aminosalicylate class catalogued in DrugCentral. It was first approved by the FDA in 1987. DrugCentral lists 7 molecular targets, including PTGS2, PTGS1 and Hao1. Recorded indications include Chronic ulcerative proctitis, Chronic ulcerative rectosigmoiditis, Ulcerative colitis and Ulcerative colitis in remission.

  • Approval status: ofp (first approved 1987 by the FDA).
  • Drug class: Aminosalicylate.
  • Molecular targets: PTGS2, PTGS1, Hao1 and TNF (7 listed in DrugCentral).
  • Indications: Chronic ulcerative proctitis, Chronic ulcerative rectosigmoiditis, Ulcerative colitis and Ulcerative colitis in remission.
  • ATC code: A07EC02 (Aminosalicylic acid and similar agents).
  • Molecular formula: C7H7NO3; molecular weight 153.14 g/mol.

The guide below was drafted with an AI model (Google Gemini) and edited automatically; it is not clinically reviewed. The data sections after it come directly from DrugCentral. How we generate and check text.

What is Mesalamine?

Mesalamine, also known by its chemical name 5-aminosalicylic acid (5-ASA), is a cornerstone medication primarily used to manage inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease. It belongs to a class of drugs known as aminosalicylates, which are specifically designed to reduce inflammation within the gastrointestinal tract. As a generic medication, mesalamine is available under various brand names, including Apriso, Asacol, Delzicol, Lialda, Pentasa, and Rowasa, among others. The choice of brand name often depends on the specific formulation and delivery system designed to target different parts of the intestine. Its efficacy lies in its ability to exert topical anti-inflammatory effects directly on the inflamed intestinal lining, making it a crucial therapeutic agent for patients seeking relief from chronic gastrointestinal symptoms.

Mechanism of Action

The precise mechanism by which mesalamine exerts its therapeutic effects is complex and not fully elucidated, but it is understood to involve multiple pathways that contribute to its anti-inflammatory action. At the molecular level, mesalamine is believed to inhibit the production of pro-inflammatory mediators. It acts as a scavenger of reactive oxygen species (ROS), thereby reducing oxidative stress, which is a significant contributor to intestinal inflammation in IBD.

Key Molecular Targets and Pathways:

  • Inhibition of Pro-inflammatory Cytokines: Mesalamine can suppress the production and activity of key cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines play a pivotal role in initiating and perpetuating the inflammatory cascade in the gut.
  • Inhibition of Arachidonic Acid Metabolism: It is thought to inhibit cyclooxygenase (COX) and lipoxygenase (LOX) pathways, which are responsible for the synthesis of inflammatory eicosanoids like prostaglandins and leukotrienes. By blocking these enzymes, mesalamine reduces the formation of these potent inflammatory molecules.
  • Modulation of Nuclear Factor-kappa B (NF-κB): Mesalamine has been shown to inhibit the activation of NF-κB, a transcription factor that regulates the expression of numerous genes involved in inflammation, immunity, and cell survival. Inhibiting NF-κB activation leads to a downstream reduction in the synthesis of inflammatory proteins.
  • Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) Activation: Some evidence suggests that mesalamine may activate PPAR-γ, a nuclear receptor that has anti-inflammatory properties and can suppress inflammatory gene expression.
  • Antioxidant Properties: As mentioned, mesalamine directly scavenges free radicals and may also enhance the activity of endogenous antioxidant enzymes, thereby protecting the intestinal mucosa from damage caused by oxidative stress.

The localized action of mesalamine within the intestinal lumen is critical. Different formulations are designed to release the active drug at specific sites along the GI tract, ensuring maximum concentration at the inflamed areas while minimizing systemic absorption and potential side effects.

Clinical Uses & Indications

Mesalamine is primarily indicated for the treatment and maintenance of remission in patients with mild to moderate ulcerative colitis. It is also used in the management of Crohn's disease, particularly for colonic involvement. The U.S. Food and Drug Administration (FDA) has approved mesalamine for the following indications:

FDA-Approved Uses:

  • Induction and Maintenance of Remission in Ulcerative Colitis: Mesalamine is a first-line therapy for inducing remission in patients with mild to moderate active ulcerative colitis and for maintaining remission in patients who have achieved clinical response.
  • Treatment of Mild to Moderate Crohn's Disease: While its efficacy in Crohn's disease is generally considered less potent than in ulcerative colitis, mesalamine can be used for managing mild to moderate cases, especially those affecting the colon.
  • Proctitis and Proctosigmoiditis: Specific formulations, particularly rectal preparations like suppositories and enemas, are highly effective for treating inflammation limited to the rectum and rectosigmoid colon.

It is important to note that while mesalamine is effective for managing inflammation, it does not cure IBD. It is typically used as part of a comprehensive treatment plan that may include other medications, dietary modifications, and lifestyle changes. The choice of formulation and dosage depends on the location and severity of the disease, as well as individual patient factors.

Dosage & Administration

Mesalamine is available in various dosage forms and strengths, designed for targeted delivery to different segments of the gastrointestinal tract. The optimal dosage and administration route depend on the specific condition being treated, its severity, and the patient's response.

Common Dosage Forms and Routes:

  • Oral Formulations: Mesalamine is available in delayed-release capsules, tablets, and extended-release granules. These formulations are designed to protect the drug from degradation in the stomach's acidic environment and release it in the small intestine or colon. Common strengths range from 250 mg to 4.4 grams per day, often divided into multiple doses. Brand names like Asacol HD, Lialda, and Apriso utilize different technologies (e.g., pH-dependent coatings, osmotic release systems) to ensure proper drug delivery.
  • Rectal Formulations: For conditions affecting the lower bowel, such as proctitis, mesalamine is administered rectally via suppositories (typically 500 mg to 1 gram) or enemas (typically 3 to 4 grams). These forms allow for direct application of the anti-inflammatory agent to the rectal mucosa.

Administration Instructions:

  • Oral formulations should generally be taken with water, and patients should be advised not to crush, chew, or break the tablets or capsules unless specifically instructed by their healthcare provider, as this can disrupt the intended release mechanism.
  • Rectal formulations are typically administered once daily, often at bedtime. Patients should follow their doctor's instructions carefully regarding insertion and retention of suppositories or enemas.

It is crucial for patients to adhere strictly to the prescribed dosage regimen to achieve and maintain therapeutic benefits. Missing doses or altering the schedule can reduce the drug's effectiveness.

Side Effects & Safety

Mesalamine is generally well-tolerated, but like all medications, it can cause side effects. The incidence and severity of side effects can vary depending on the formulation, dosage, and individual patient sensitivity.

Common Side Effects:

These are typically mild and may include:

  • Headache
  • Nausea
  • Abdominal pain or cramping
  • Diarrhea
  • Flatulence
  • Dizziness

Serious Side Effects:

Although rare, more severe side effects can occur and require immediate medical attention. These include:

  • Allergic Reactions: Symptoms may include rash, itching, hives, difficulty breathing, swelling of the face, lips, tongue, or throat.
  • Kidney Problems: Mesalamine can potentially cause kidney damage, characterized by changes in urination (frequency or amount), swelling, or unexplained weight gain. Nephrotic syndrome and interstitial nephritis have been reported.
  • Liver Problems: Although less common, liver dysfunction may occur, presenting as jaundice (yellowing of the skin or eyes), dark urine, or persistent nausea/vomiting.
  • Severe Skin Reactions: Rare but serious reactions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) can occur, characterized by blistering, peeling skin, and fever.
  • Blood Dyscrasias: Rarely, mesalamine can affect blood cell counts, leading to increased risk of infection or bleeding.
  • Pancreatitis: Inflammation of the pancreas is a potential, albeit uncommon, side effect.
  • Pulmonary Reactions: Symptoms like shortness of breath, cough, chest pain, and fever might indicate lung inflammation (e.g., eosinophilic pneumonia, interstitial lung disease).

Contraindications:

Mesalamine should not be used in patients with:

  • Known hypersensitivity to mesalamine, aminosalicylates, or any component of the formulation.
  • History of hypersensitivity reactions to salicylates (e.g., aspirin), although cross-reactivity is not guaranteed.
  • Certain conditions like intestinal or pyloric obstruction (for oral formulations).

Patients with pre-existing kidney or liver disease should use mesalamine with caution and under close medical supervision. Regular monitoring of kidney and liver function is recommended, especially with long-term use or higher doses.

Drug Interactions

While mesalamine has a relatively favorable safety profile, potential drug interactions can occur, altering its efficacy or increasing the risk of adverse effects. It is essential for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking.

Notable Drug Interactions:

  • Warfarin: Mesalamine may increase the anticoagulant effect of warfarin, potentially raising the risk of bleeding. Close monitoring of prothrombin time (PT) or International Normalized Ratio (INR) is advised when these drugs are used concurrently.
  • Other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): Concurrent use of mesalamine with other NSAIDs, such as ibuprofen or naproxen, may increase the risk of gastrointestinal toxicity (e.g., ulcers, bleeding) and kidney problems due to additive effects on the GI mucosa and renal function.
  • Azathioprine, Mercaptopurine, Thioguanine: Mesalamine might potentially increase the myelosuppressive effects of these immunosuppressants. Careful monitoring of blood counts is recommended.
  • Diuretics: Mesalamine's potential to cause kidney problems could be exacerbated by concurrent use of diuretics, particularly thiazide diuretics, which can also affect renal function.
  • Certain Antacids: Some formulations of mesalamine are designed for specific release profiles. Antacids containing magnesium may interfere with the absorption or efficacy of certain delayed-release formulations.

Patients should always consult their physician or pharmacist regarding potential interactions before starting or stopping any medication while on mesalamine therapy.

Molecular Properties

Understanding the molecular characteristics of mesalamine is fundamental to appreciating its behavior and interactions within the body. Its chemical structure dictates its solubility, absorption, distribution, metabolism, and excretion (ADME) properties, as well as its interaction with biological targets.

Key Molecular Data:

  • Chemical Name: 5-aminosalicylic acid
  • Molecular Formula: C7H7NO3
  • Molecular Weight: 153.14 g/mol
  • Structure Description: Mesalamine is an aromatic compound consisting of a benzene ring substituted with three functional groups: an amino group (-NH2), a hydroxyl group (-OH), and a carboxylic acid group (-COOH). Specifically, it is a derivative of salicylic acid (2-hydroxybenzoic acid), with an amino group attached at the 5-position relative to the carboxylic acid group. The presence of both acidic (carboxylic acid) and basic (amino) groups, along with a phenolic hydroxyl group, influences its physicochemical properties, including its amphoteric nature and solubility.
  • SMILES Notation: Nc1ccc(O)c(C(=O)O)c1. This notation provides a unique, linear representation of the molecule's structure, where 'N' denotes nitrogen, 'c' represents aromatic carbon atoms, 'O' denotes oxygen, and the numbers and symbols describe the connectivity and arrangement of atoms and bonds.

The specific arrangement of these functional groups on the benzene ring is crucial for mesalamine's pharmacological activity. The hydroxyl and carboxylic acid groups are characteristic of salicylates, while the amino group contributes to its specific anti-inflammatory properties and influences its reactivity and distribution within the body.

Analyze Mesalamine with MolForge

Exploring the intricate molecular properties, potential drug interactions, and therapeutic mechanisms of mesalamine is essential for researchers and pharmaceutical professionals aiming to develop improved therapeutics or understand existing ones better. MolForge's AI-powered platform offers advanced tools to explore the characteristics of molecules like mesalamine.

Leverage MolForge's capabilities to:

  • Visualize the 3D structure of mesalamine and its derivatives.
  • Predict potential off-target interactions and toxicity profiles.
  • Analyze structure-activity relationships (SAR) to design novel compounds with enhanced efficacy or reduced side effects.
  • Explore metabolic pathways and potential drug-drug interactions with greater precision.

Discover the future of molecular discovery. Visit the MolForge dashboard today to unlock the full potential of AI in pharmaceutical research and development.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

  • Chronic ulcerative proctitis
  • Chronic ulcerative rectosigmoiditis
  • Ulcerative colitis
  • Ulcerative colitis in remission

Off-label uses (1)

  • Crohn's disease

Contraindications (7)

  • Anemia
  • Disease of liver
  • Interstitial nephritis
  • Kidney disease
  • Minimal change disease
  • Neutropenic disorder
  • Pyloric obstruction

Mechanism & targets

Established pharmacologic classAminosalicylate

Molecular targets (7)

TargetGeneActionActivity
Prostaglandin G/H synthase 2PTGS2inhibitorIC50 5.12
Prostaglandin G/H synthase 1PTGS1unknownIC50 5.11
Hydroxyacid oxidase 1Hao1unknownIC50 5.11
Tumor necrosis factorTNFunknownIC50 4.70
Peroxisome proliferator-activated receptor gammaPPARGagonist—
Prostaglandin G/H synthase 1PTGS1inhibitor—
Arachidonate 5-lipoxygenaseALOX5inhibitor—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1987-12-24FDA—MEDA PHARMS

ATC classification

ATC codeTherapeutic hierarchy
A07EC02ALIMENTARY TRACT AND METABOLISM › ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS › INTESTINAL ANTIINFLAMMATORY AGENTS › Aminosalicylic acid and similar agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Colitis ulcerative7219.3
Haematochezia3593.5
Frequent bowel movements2941.0
Condition aggravated2044.2
Off label use2004.5
Inappropriate schedule of product administration1369.7
Intentional product use issue1174.0
Rectal haemorrhage1161.1
Faecal calprotectin increased980.5
Death805.8
Colitis780.1
Mucous stools768.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Mesalamine is on its molecule page.

Molecular formulaC7H7NO3
Molecular weight153.14 g/mol
CAS number89-57-6
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N
PubChem CID4075
NC1=CC(C(O)=O)=C(O)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Mesalamine used for?

DrugCentral lists the following indications for Mesalamine: Chronic ulcerative proctitis, Chronic ulcerative rectosigmoiditis, Ulcerative colitis and Ulcerative colitis in remission.

How does Mesalamine work?

Its molecular targets in DrugCentral include PTGS2 (inhibitor), PTGS1, Hao1 and TNF.

When was Mesalamine first approved?

Mesalamine was first approved by the FDA in 1987.

What drug class does Mesalamine belong to?

Mesalamine is in the Aminosalicylate class.

What is the chemical formula of Mesalamine?

Mesalamine has the molecular formula C7H7NO3 and a molecular weight of 153.14 g/mol.

Analyze Mesalamine with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Ask About Mesalamine

Have a question? Our AI can help (answers are AI-generated, not medical advice).

Browse: Gastrointestinal drug guides · all drugs starting with M · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases and includes AI-generated text. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.